John B. Moriarty - Jun 23, 2023 Form 3 Insider Report for Mirati Therapeutics, Inc. (MRTX)

Role: Chief Legal Officer
Signature: /s/ Betsy Gelfand, Attorney-in-Fact
Stock symbol: MRTX
Transactions as of: Jun 23, 2023
Transactions value $: $0
Form type: 3
Date filed: 6/23/2023, 05:15 PM
Previous filing: Feb 2, 2023
Next filing: Aug 10, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MRTX	Common Stock						49.4K	Jun 23, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MRTX	Employee Stock Option (Right to Buy)							Jun 23, 2023	Common Stock	83.5K	$45.88	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This represents a Restricted Stock Unit grant with a vesting period of 4 years that vests 25% annually from grant date, which was May 1, 2023.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, which was May 1, 2023 and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.